Results 181 to 190 of about 133,265 (260)

Treatment Outcomes With Novel Targeted and Immunotherapeutic Regimens in CAYA Hodgkin Lymphoma: A Retrospective Study

Cancer Innovation, Volume 5, Issue 2, April 2026.
Compared to conventional chemotherapy, treatment with BV‐AVD ± R in CAYA Hodgkin lymphoma patients resulted in comparable response rates (ORR: 96.4% vs. 95.4%) but with a marked reduction in Grade 4 hematologic toxicity (25.6% vs. 61.2%). BV‐AVD monotherapy yielded a higher ORR than BV‐AVD + R (100% vs. 93.9%).
Mengqing Xie, Meng Yuan, Mengwei Ren, Jing Tian, Shengyu Zhou, Xiaohui He, Yan Qin, Peng Liu, Jianliang Yang, Mengyuan Han, Fei Ma, Sheng Yang, Sidan Li   +12 more
wiley   +1 more source

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B-Cell Non-Hodgkin Lymphoma: Results From the Phase 1b J-MIND Study. [PDF]

Cancer Sci
Izutsu K, Fukuhara N, Yuda J, Suehiro Y, Kusumoto S, Casadebaig ML, Suzukawa K, Fukushima K.   +7 more
europepmc   +1 more source

Combining Small‐Molecular Compounds With CAR T‐Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy

Cancer Innovation, Volume 5, Issue 2, April 2026.
Chimeric antigen receptor (CAR) T‐cell therapy, although revolutionary for haematological malignancies, faces significant challenges, including T‐cell exhaustion, limited persistence, and treatment‐related toxicity. The integration of small‐molecule compounds offers a promising strategy to overcome these limitations.
Rangzi Yi, Zijian Zhang, Yang Yang, Haichuan Zhu   +3 more
wiley   +1 more source

HIV infection complicated with talaromyces marneffei, tuberculosis, hemophagocytic lymphohistiocytosis and non-Hodgkin lymphoma: a complex case report. [PDF]

BMC Infect Dis
Fu W, Deng ZW, Wang P, Zhu ZW, Xie ZB, Li YZ, Zhang HQ, Yu HY.   +7 more
europepmc   +1 more source

Standardizing the Clinical Approach to Cancer Therapy‐Related Cardiac Dysfunction: Applying Cardio‐Oncology Guidelines as a Practical Tool for Hematology and Oncology Providers

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Introduction and Methods Cancer therapy–related cardiac dysfunction (CTRCD) is a well established and potentially life‐threatening complication of contemporary oncologic treatment. Although comprehensive cardio‐oncology guidelines have been developed, their integration into routine hematology and oncology practice remains inconsistent.
Abdelrahman Ali, Suparna C. Clasen, Anne Blaes, Stephen Casselli, Anita Deswal, Susan Halli Demeter, Gregory Durm, Anecita Fadol, Alessandra Ferrajoli, Michael G. Fradley, Joerg Herrmann, Borja Ibanez, Sue Koob, Bogda Koczwara, Kasey J. Leger, Jennifer E. Liu, Teresa López‐Fernández, Alexander R. Lyon, N. G. Choon Ta, John Teerlink, Eric H. Yang, Susan Dent, Daniel Lenihan   +22 more
wiley   +1 more source

Effect of blueberry extract on enhancement of radiosensitivity in non-Hodgkin lymphoma by modulating proliferation and apoptosis. [PDF]

Daru
Moradloo N, Arab S, Jam HR, Asgharzadeh S, Shokri S, Nasehi L, Nokhodchi A.   +6 more
europepmc   +1 more source

Nationwide Incidence, Treatment Pattern, and Prognosis of Primary CNS Lymphoma in Taiwan, 2012–2020: A Retrospective Cohort Study

Cancer Medicine, Volume 15, Issue 4, April 2026.
Using data from the Taiwan Cancer Registry, the Taiwan National Health Insurance Research Database, and the Taiwan National Death Registry, this nationwide real‐world study examined the epidemiology, treatment patterns, prognosis, medical costs, and adverse events associated with primary central nervous system lymphoma (PCNSL) in Taiwan over a nine ...
Fei‐Yuan Hsiao, Hung‐Yu Lin, Ho‐Min Chen, Wan‐Hsuan Hsu, Bor‐Sheng Ko   +4 more
wiley   +1 more source

The prognostic utility of a combined PNI-HB immunonutritional index in CD19 CAR T-cell therapy for relapsed/refractory non-Hodgkin lymphoma. [PDF]

iScience
Liu Y, Chen X, Li P, Hao W, Luo X, Zhang W, Lu H, Xue B, Liang A.   +8 more
europepmc   +1 more source

Sustained Belinostat‐Induced Metabolic Response and Tolerability in Heavily Pretreated Relapsed/Refractory Angioimmunoblastic T‐Cell Lymphoma: A Case Report

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT Angioimmunoblastic T‐cell lymphoma (AITL), a rare and aggressive subtype of peripheral T‐cell lymphoma (PTCL), often demonstrates resistance to standard therapies. The optimal therapeutic approach for relapsed/refractory (R/R) AITL remains therefore uncertain and challenging, with an unmet need for effective treatment options.
Vassiliki Labropoulou, Evgenia Verigou, Eleni P. Kourea, Maria Liga, Dimitrios Tsokanas, Krisela‐Christina Valera, Alexandros Spyridonidis   +6 more
wiley   +1 more source

Outcomes of point-of-care manufactured CAR T cell therapy for B cell acute lymphoblastic leukemia and non-Hodgkin lymphoma in Vietnam. [PDF]

Mol Ther Oncol
Nguyen LT, Nguyen DD, Bach QK, Dao LTM, Phan TTK, Nguyen HP, Dao HN, Pham TH, Pham PT, Mai HT, Pham VHT, Nguyen TMT, Le VB, Phung NL, Nguyen NQ, Hermiston ML, Phan QL, Nguyen DQT, Mai L, Nguyen QN, Hoang VT.   +20 more
europepmc   +1 more source